Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.56 |
| ▸ | NOS2 | P35228 | 4/20 | 0.56 |
| ▸ | NOS1 | P29475 | 2/20 | 0.56 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | GABRE | P78334 | 1/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851068 | 1.00 | NOS3 (0.56) | NOS3NOS2NOS1GABRPGABRD | |
| Formic Acid SCHEMBL30949963 | 0.89 | NOS3 (0.46) | NOS3NOS2NOS1GABRPGABRD | |
| Trifluoroacetic Acid SCHEMBL30165039 | 0.88 | GABRP (0.51) | NOS3NOS2NOS1GABRPGABRD | |
| Trifluoroacetic Acid SCHEMBL30165134 | 0.88 | GABRP (0.51) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL30493743 | 0.84 | NOS3 (0.52) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL29899421 | 0.83 | NOS3 (0.56) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL6933510 | 0.83 | NOS3 (0.56) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL14803741 | 0.81 | NOS3 (0.58) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL16712832 | 0.80 | CA2 (0.45) | NOS3NOS2NOS1PIK3CDCA2 | |
| SCHEMBL13073943 | 0.78 | UHRF1 (0.46) | HPGDHSD17B10S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4305038-A1 | KRAS G12D INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-01-17 | — | — | EP | claimed |
| WO-2022192794-A1 | KRAS G12D INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | claimed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4709371-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4577214-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250197424-A1 | QUINOLINE COMPOUND AND USE THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| WO-2023001123-A1 | NEW PYRIDOPYRIMIDINE DERIVATIVE | 上海艾力斯医药科技股份有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2023274324-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-01-05 | — | — | WO | disclosed |
| WO-2023274324-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-01-05 | — | — | WO | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022216762-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022192794-A1 | KRAS G12D INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2022173678-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-112105419-A | Fused ring compound | 豪夫迈·罗氏有限公司 | 2020-12-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | NOS3 4696/4885NOS2 4592/4885NOS1 4756/4885 |
| US-20250197424-A1 | QUINOLINE COMPOUND AND USE THEREOF | UGT1A7, UGT2B7, CYP3A7 | NOS3 487/4885NOS2 442/4885NOS1 715/4885 |
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | NOS3 2513/4885NOS2 3956/4885NOS1 2957/4885 |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | OXA1L, CACNA1I, GRIK5 | NOS3 4712/4885NOS2 4718/4885NOS1 4805/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | NOS3 4189/4885NOS2 4824/4885NOS1 4399/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | NOS3 3977/4885NOS2 4519/4885NOS1 3932/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | NOS3 2942/4885NOS2 3747/4885NOS1 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.